IANS Press Release

Art of Healing Cancer, one of the leading organizations focused on precision oncology to treat cancer patients, is raising awareness about the high cost of immunotherapy treatment in India by sharing important information on the subject. The organization aims to shed light on the financial burden patients and their families face, advocating for greater accessibility to this life-saving treatment option.

Art of Healing Cancer, a globally renowned Precision and integrative oncology institution located in Gurgaon, underscores the possible benefits of incorporating the anti-malarial drug, Artesunate, into cancer treatments. This insight could introduce novel approaches to enhance the effectiveness of traditional cancer therapies.

Sentinel Lymph Node Biopsy (SLNB) is a crucial diagnostic procedure that helps physicians identify and evaluate the first lymph node(s) affected by cancer, known as the sentinel lymph node(s). This assessment is crucial in determining whether cancer has spread beyond its primary site.

In the field of cancer research, the tireless efforts of doctors and scientists have led to remarkable breakthroughs in recent years. Innovative work has resulted in the development of new drugs, medicines, and therapies that can either cure or extend the lives of cancer patients.

Art of Healing Cancer, a leading cancer care provider in India, is pleased to share information on the role of liquid biopsy in the management of cancer. This technique is revolutionising cancer care by providing a non-invasive and more accurate way of detecting cancer and monitoring its progression.

Cervical cancer is the fifth most common cancer among women globally according to World Health Organization (WHO). India accounts for one-fifth (1/5th ) of the global burden of the disease. Every year in India, approximately 1.23 lakh women are diagnosed with cervical cancer and around 67,000 die from the disease. It is the second most common cancer affecting women in India.

In 2020, the combined age-standardised rate for all cancers, excluding non-melanoma skin cancer, was 190 per 100,000, and men had a greater rate of developing cancer (206.9 per 100,000) than women (178.1 per 100,000).